Risk of echocardiographic pulmonary hypertension in individuals with human immunodeficiency virus-hepatitis c virus coinfection

Annals of the American Thoracic Society

Volumn 11, Issue 10, 2014, Pages 1553-1559

  Sangal, Rohit B ^a   Taylor, Lynn E ^a,b   Gillani, Fizza ^a,b   Poppas, Athena ^b,c   Klinger, James R ^a,d   Ventetuolo, Corey E ^a,d  

^a BROWN UNIVERSITY   (United States)

^b Division of Infectious Diseases   (United States)

^c Lifespan   (United States)

^d RHODE ISLAND HOSPITAL   (United States)

Author keywords

Echocardiography; Hepatitis C; Human immunodeficiency virus; Interferon; Pulmonary hypertension

Indexed keywords

BOCEPREVIR; HEMOGLOBIN; HEPATITIS C VIRUS ANTIBODY; INTERFERON; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ADULT; AORTA VALVE DISEASE; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; ECHOCARDIOGRAPHY; FEMALE; GENOTYPE; HEART ATRIUM ENLARGEMENT; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RIGHT VENTRICLE FUNCTION; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE DISEASE; MIXED INFECTION; PREVALENCE; PULMONARY ARTERY SYSTOLIC PRESSURE; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; RISK FACTOR; SMOKING; SYSTOLIC BLOOD PRESSURE; VIRUS LOAD; COMPLICATION; ECHOGRAPHY; FOLLOW UP; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS; HYPERTENSION, PULMONARY; LUNG WEDGE PRESSURE; MIDDLE AGED; ODDS RATIO; UNITED STATES;

COINFECTION; ECHOCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV; HIV INFECTIONS; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; ODDS RATIO; PREVALENCE; PULMONARY WEDGE PRESSURE; RETROSPECTIVE STUDIES; RHODE ISLAND; RISK FACTORS;

EID: 84920398335     PISSN: 23296933     EISSN: 23256621     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201405-225OC     Document Type: Article

References (40)

1. Mehta NJ, Khan IA, Mehta RN, Sepkowitz DA. HIV-related pulmonary hypertension: Analytic review of 131 cases. Chest 2000;118: 1133-1141.
2. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, Gomez Sanchez MA, Krishna Kumar R, Landzberg M, Machado RF, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013;62:D34-D41.
3. Opravil M, Pechère M, Speich R, JollerJemelka HI, Jenni R, Russi EW, Hirschel B, Lüthy R. HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. Am J Respir Crit Care Med 1997;155:990-995.
4. Sitbon O, Lascoux-Combe C, Delfraissy JF, Yeni PG, Raffi F, De Zuttere D, Gressin V, Clerson P, Sereni D, Simonneau G. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med 2008;177: 108-113.
5. Speich R, Jenni R, Opravil M, Pfab M, Russi EW. Primary pulmonary hypertension in HIV infection. Chest 1991;100:1268-1271.
6. Cool CD, Voelkel NF, Bull T. Viral infection and pulmonary hypertension: is there an association? Expert Rev Respir Med 2011; 5:207-216.
7. Hofman FM, Wright AD, Dohadwala MM, Wong-Staal F, Walker SM. Exogenous tat protein activates human endothelial cells. Blood 1993;82:2774-2780.
8. Humbert M, Monti G, Brenot F, Sitbon O, Portier A, Grangeot-Keros L, Duroux P, Galanaud P, Simonneau G, Emilie D. Increased interleukin- 1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 1995;151: 1628-1631.
9. James CO, Huang MB, Khan M, Garcia-Barrio M, Powell MD, Bond VC. Extracellular Nef protein targets CD41 T cells for apoptosis by interacting with CXCR4 surface receptors. J Virol 2004;78: 3099-3109.
10. Almodovar S, Hsue PY, Morelli J, Huang L, Flores SC; Lung HIV Study. Pathogenesis of HIV-associated pulmonary hypertension: Potential role of HIV-1 Nef. Proc Am Thorac Soc 2011;8:308-312.
11. Marecki JC, Cool CD, Parr JE, Beckey VE, Luciw PA, Tarantal AF, Carville A, Shannon RP, Cota-Gomez A, Tuder RM, et al. HIV-1 Nef is associated with complex pulmonary vascular lesions in SHIV-nefinfected macaques. Am J Respir Crit Care Med 2006;174:437-445.
12. Almodovar S, Knight R, Allshouse AA, Roemer S, Lozupone C, McDonald D, Widmann J, Voelkel NF, Shelton RJ, Suarez EB, et al. Human immunodeficiency virus nef signature sequences are associated with pulmonary hypertension. AIDS Res Hum Retroviruses 2012;28:607-618.
13. Taylor LE, Swan T, Mayer KH. HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms. Clin Infect Dis 2012;55:S33-S42.
14. Spikes L, Dalvi P, Tawfik O, Gu H, Voelkel NF, Cheney P, O'Brien- Ladner A, Dhillon NK. Enhanced pulmonary arteriopathy in simian immunodeficiency virus-infected macaques exposed to morphine. Am J Respir Crit Care Med 2012;185:1235-1243.
15. Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, Degenhardt L. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011; 378:571-583.
16. Taylor LE, Swan T, Matthews GV. Management of hepatitis C virus/HIV coinfection among people who use drugs in the era of direct-acting antiviral-based therapy. Clin Infect Dis 2013;57:S118-S124.
17. Badiger R, Mitchell JA, Gashaw H, Galloway-Phillipps NA, Foser S, Tatsch F, Singer T, Hansel TT, Manigold T. Effect of different interferona2 preparations on IP10 and ET-1 release from human lung cells. PLoS One 2012;7:e46779.
18. Dhillon S, Kaker A, Dosanjh A, Japra D, Vanthiel DH. Irreversible pulmonary hypertension associated with the use of interferon alpha for chronic hepatitis C. Dig Dis Sci 2010;55:1785-1790.
19. Reiberger T, Payer BA, Ferlitsch A, Sieghart W, Breitenecker F, Aichelburg MC, Schmied B, Rieger A, Trauner M, Peck-Radosavljevic M; Vienna Hepatic Hemodynamic Lab and Vienna HIV & Liver Study Group. A prospective evaluation of pulmonary, systemic and hepatic haemodynamics in HIV-HCV-coinfected patients before and after antiviral therapy with pegylated interferon and ribavirin. Antivir Ther 2012;17:1327-1334.
20. Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: An update. Hepatology 2009;49:1335-1374.
21. Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K, Solomon SD, Louie EK, Schiller NB. Guidelines for the echocardiographic assessment of the right heart in adults: A report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 2010;23: 685-713, quiz 786-788.
22. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, et al.; Chamber Quantification Writing Group; American Society of Echocardiography's Guidelines and Standards Committee; European Association of Echocardiography. Recommendations for chamber quantification: A report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18: 1440-1463.
23. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, Waggoner AD, Flachskampf FA, Pellikka PA, Evangelisa A. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr 2009;10:165-193.
24. Mondy KE, Gottdiener J, Overton ET, Henry K, Bush T, Conley L, Hammer J, Carpenter CC, Kojic E, Patel P, et al.; SUN Study Investigators. High prevalence of echocardiographic abnormalities among HIV-infected persons in the era of highly active antiretroviral therapy. Clin Infect Dis 2011;52:378-386.
25. Kcomt W, Nahavandi AA, Myaing M, Alkhalil C, Stein D. Hepatitis C and the heart: To beat or not to beat. Int J Cardiol 2004;96:147-149.
26. Kawut SM, Krowka MJ, Trotter JF, Roberts KE, Benza RL, Badesch DB, Taichman DB, Horn EM, Zacks S, Kaplowitz N, et al.; Pulmonary Vascular Complications of Liver Disease Study Group. Clinical risk factors for portopulmonary hypertension. Hepatology 2008;48: 196-203.
27. Moorman J, Saad M, Kosseifi S, Krishnaswamy G. Hepatitis C virus and the lung: implications for therapy. Chest 2005;128:2882-2892.
28. Moon EJ, Jeong CH, Jeong JW, Kim KR, Yu DY, Murakami S, Kim CW, Kim KW. Hepatitis B virus X protein induces angiogenesis by stabilizing hypoxia-inducible factor-1alpha. FASEB J 2004;18: 382-384.
29. Spradling PR, Richardson JT, Buchacz K, Moorman AC, Finelli L, Bell BP, Brooks JT, Investigators HIVOS; HIV Outpatient Study Investigators. Trends in hepatitis C virus infection among patients in the HIV Outpatient Study, 1996-2007. J Acquir Immune Defic Syndr 2010;53:388-396.
30. Caravita S, Secchi MB, Wu SC, Pierini S, Paggi A. Sildenafil therapy for interferon-b-1a-induced pulmonary arterial hypertension: A case report. Cardiology 2011;120:187-189.
31. Savale L, Gunther S, Chaumais MC, Jais X, Sattler C, Macari EA, Montani D, Simonneau G, Humbert M, Sitbon O. Pulmonary arterial hypertension in patients treated with interferon; 2013 [accessed 2014 May]. Available from: https://www.ersnetsecure.org/public/prg-congres.abstract?ww-i-presentation=63109.
32. Fruehauf S, Steiger S, Topaly J, Ho AD. Pulmonary artery hypertension during interferon-alpha therapy for chronic myelogenous leukemia. Ann Hematol 2001;80:308-310.
33. Jochmann N, Kiecker F, Borges AC, Hofmann MA, Eddicks S, Sterry W, Baumann G, Trefzer U. Long-term therapy of interferon-alpha induced pulmonary arterial hypertension with different PDE-5 inhibitors: A case report. Cardiovasc Ultrasound 2005;3:26.
34. Foster GR, Zeuzem S, Pianko S, Sarin SK, Piratvisuth T, Shah S, Andreone P, Sood A, Chuang WL, Lee CM, et al. Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin. J Viral Hepat 2013;20: e115-e123.
35. George PM, Mitchell JA. Evidence that pulmonary vascular pathology explains the decline in lung function associated with interferon a based therapies for chronic hepatitis C virus. J Viral Hepat 2013;20: 592.
36. Wort SJ, Ito M, Chou PC, McMaster SK, Badiger R, Jazrawi E, de Souza P, Evans TW, Mitchell JA, Pinhu L, et al. Synergistic induction of endothelin-1 by tumor necrosis factor alpha and interferon gamma is due to enhanced NF-kappaB binding and histone acetylation at specific kappaB sites. J Biol Chem 2009;284:24297-24305.
37. George PM, Badiger R, Alazawi W, Foster GR, Mitchell JA. Pharmacology and therapeutic potential of interferons. Pharmacol Ther 2012;135:44-53.
38. Hanaoka M, Kubo K, Hayano T, Koizumi T, Kobayashi T. Interferonalpha elevates pulmonary blood pressure in sheep-the role of thromboxane cascade. Eur J Pharmacol 1999;370:145-151.
39. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, et al.; American College of Cardiology Foundation Task Force on Expert Consensus Documents; American Heart Association; American College of Chest Physicians; American Thoracic Society, Inc; Pulmonary Hypertension Association. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009;53:1573-1619.
40. Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, Langleben D, Manes A, Satoh T, Torres F, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 2013;62: D42-D50.